Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Salituro

Showing results (41-50 of 47) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 47 results.
Science (New York, N.Y.)|April 6, 2013
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiationFang Wang, Jeremy Travins, Byron DeLaBarre, et al.
Chemistry & Biology|September 25, 2012
Small molecule activation of PKM2 in cancer cells induces serine auxotrophyCharles Kung, Jeff Hixon, Sung Choe, et al.
ACS Medicinal Chemistry Letters|April 20, 2018
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersJaneta Popovici-Muller, René M Lemieux, Erin Artin, et al.
Cancer Discovery|February 15, 2017
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Jeremy Travins, Fang Wang, et al.
Journal of Medicinal Chemistry|August 1, 2015
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune DiseasesLuc J Farmer, Mark W Ledeboer, Thomas Hoock, et al.
Journal of Medicinal Chemistry|July 15, 2014
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2Michael P Clark, Mark W Ledeboer, Ioana Davies, et al.
Nature Chemical Biology|August 28, 2012
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesisDimitrios Anastasiou, Yimin Yu, William J Israelsen, et al.
Pageof 5

Showing results (41-50 of 47) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 47 results.
Science (New York, N.Y.)|April 6, 2013
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiationFang Wang, Jeremy Travins, Byron DeLaBarre, et al.
Chemistry & Biology|September 25, 2012
Small molecule activation of PKM2 in cancer cells induces serine auxotrophyCharles Kung, Jeff Hixon, Sung Choe, et al.
ACS Medicinal Chemistry Letters|April 20, 2018
Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant CancersJaneta Popovici-Muller, René M Lemieux, Erin Artin, et al.
Cancer Discovery|February 15, 2017
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> MutationsKatharine Yen, Jeremy Travins, Fang Wang, et al.
Journal of Medicinal Chemistry|August 1, 2015
Discovery of VX-509 (Decernotinib): A Potent and Selective Janus Kinase 3 Inhibitor for the Treatment of Autoimmune DiseasesLuc J Farmer, Mark W Ledeboer, Thomas Hoock, et al.
Journal of Medicinal Chemistry|July 15, 2014
Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2Michael P Clark, Mark W Ledeboer, Ioana Davies, et al.
Nature Chemical Biology|August 28, 2012
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesisDimitrios Anastasiou, Yimin Yu, William J Israelsen, et al.
Pageof 5